Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827537 | 0.86 | ACHE (0.35) | DGAT1ACHE | |
| SCHEMBL21581167 | 0.82 | — | — | |
| SCHEMBL14944623 | 0.82 | — | — | |
| SCHEMBL2983095 | 0.81 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL9638271 | 0.80 | DGAT1 (0.41) | DGAT1ACHE | |
| SCHEMBL1488779 | 0.79 | KMT2A (0.43) | DGAT1 | |
| Hydrochloric Acid SCHEMBL15455783 | 0.78 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL17810435 | 0.78 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL1126106 | 0.78 | TLR8 (0.47) | DGAT1 | |
| SCHEMBL6531325 | 0.78 | DGAT1 (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-11-28 | — | — | US | disclosed |
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2776439-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-04 | — | — | EP | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| CN-101466686-A | C-FMS kinase inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | CN | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-5710153-A | INTERLEUKIN CONVERTING ENZYME INHIBITORS | ONO PHRAMACEUTICAL CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
| EP-0761680-A2 | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5147863-A | 2,2'-bi-1H-imidazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-15 | — | — | US | disclosed |
| EP-0229922-B1 | NOVEL 2,2'-BI-1H-IMIDAZOLES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | PNP, ADA, HPRT1 | DGAT1 2481/4885ACHE 3494/4885 |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | PNP, HPRT1, TYMP | DGAT1 2540/4885ACHE 3923/4885 |
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | DGAT1 4713/4885ACHE 4495/4885 |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | DGAT1 2481/4885ACHE 3494/4885 |
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | DGAT1 2481/4885ACHE 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.